Company intelligence / Profile preview

General Proximity

San Francisco, California, United States

Ownership: Private
Employees: ~15
Development stage: Other

Overview

General Proximity emerged from stealth in 2025 with $16M in funding to advance a platform (OmniTAC) for induced-proximity medicines targeting undruggable proteins; its programs are in the pre-clinical stage with no clinical readouts yet.

Therapeutic areas: CardiovascularNeurologyOtherOncology
Modalities: Small moleculeTargeted protein degraderProteolysis-targeting chimera therapyProximity-induced small molecule therapy
Industry: Biotech

Beyond the preview

Go deeper on General Proximity.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on General Proximity.

Explore the full profile